New York News in Research: April  2017
State Budget Includes $20M Investment in Med School Research Funding

New York's 16 medical schools are ready to boost the state economy, thanks to the $20 million Governor Cuomo and the state legislature invested in medical school research through the just-passed state budget.  That investment will be matched by the medical schools 2:1 and will be used to create new labs that will be economic drivers, creating well-paying research jobs across the state.  The biomedical research conducted at those labs will also lead to better treatment and cures for diseases that ail New York's residents. The schools, which stretch from Buffalo and Rochester to Long Island, say the benefits from the state investment could be immediate -- schools are teed-up to hire staff and build out labs as soon as the state releases the funding.

Federal Budget Cuts Could Threaten Research Institutions

News 12 Long Island visited Hofstra Northwell School of Medicine and the Feinstein Institute to talk with AMSNY about how proposed cuts to the NIH could devastate local research institutions Take a closer look.

Columbia University Medical Center: Radiologists Developing Better Ways to Track Tumors

Columbia University Medical Center and NewYork-Presbyterian, in coordination with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, is launching a three-year research collaboration to develop new methods for analyzing digital images that track a patient's response to cancer therapy Take a closer look.
Weill Cornell Medicine: Women with Healthy BMI May Have Increased Risk of Breast Cancer

Women with a healthy body mass index (BMI) may be at risk of developing breast cancer because of enlarged fat cells in their breast tissue that trigger an inflammatory process, according to a new study.   Take a closer look.
Hofstra Northwell School of Medicine: Exploring a New Treatment for Brain Tumors

Marc Symons, PhD, professor in The Feinstein Institute for Medical Research's Karches Center for Oncology Research, is examining if a common medication administered to treat pinworms, could replace the current treatment used for certain brain cancers. These findings could help to extend the lives of patients suffering from one of the most common types of brain tumors - low-grade glioma.   Take a closer look.
NYU Langone Medical Center: Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease

Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack, and death in people with pre-existing coronary artery disease, according to a study published online in the New England Journal of Medicine.  Take a closer look.
NYIT College of Osteopathic Medicine: Peripheral Arteries may be Reliable Indicators of Coronary Vascular Disease

  Having reliable points of ultrasound for assessing a patient's risk for ischemic cardiovascular disease is an important diagnostic tool. Member Brian Beatty, Assistant Professor at the New York Institute of Technology (NYIT) School of Osteopathic Medicine, and colleagues, studied the arteries of 48 cadavers to determine risk factors for atherosclerosis.   Take a closer look.
Icahn School of Medicine at Mount Sinai: Epigenetic Alteration a Promising New Drug Target for Heroin Use Disorder

Heroin use is associated with excessive histone acetylation, an epigenetic process that regulates gene expression, and more years of drug use correlate with higher levels of hyperacetylation, according to research conducted at The Icahn School of Medicine at Mount Sinai and published April 1 in the journal Biological Psychiatry Take a closer look.
NYU Langone Medical Center: New Gene-Based Blood Tests Identify More Skin Cancers

Genetic testing of tumor and blood fluid samples from people with and without one of the most aggressive forms of skin cancer has shown that two new blood tests can reliably detect previously unidentifiable forms of the disease.   Take a closer look.
University of Rochester Medical Center Plays Key Role in New Huntington's Drug

URMC researchers were instrumental in the U.S. Food and Drug Administration's (FDA) recent approval of SD-809 (deutetrabenazine) to treat Huntington's disease.  Deutetrabenazine is the only the second drug authorized by the agency to treat this rare, inherited neurodegenerative disorder.  Take a closer look.
SUNY Downstate Medical Center: Lack of Oxygen, Not Excessive Stimulation, Cause for Half of Seizure-Related Brain Damage in Epilepsy

Neuronal degeneration is the most severe long-term consequence of repetitive seizures in patients with epilepsy, which until now was thought to be primarily caused by excitotoxicity, or over-stimulation of the neurons. New findings indicate hypoxia, or lack of oxygen, due to abnormal blood flow may be to blame for as much as half the neuronal death caused by the condition.   Take a closer look.
Icahn School of Medicine at Mount Sinai Researchers Review Progress of Treating Glutamate Signalling in Depression

Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy. Ketamine, which has been repurposed as a rapidly acting antidepressant, has emerged as an experimental and potentially promising compound to treat severe depression through a novel drug action mechanism that blocks glutamate receptors.  Take a closer look.
SUNY Downstate Medical Center: Locked-In ALS Patients Answer Yes or No Questions with Wearable fNIRS Device

Functional near infrared spectroscopic (fNIRS) imaging (pronounced f-nears) has led to a breakthrough in communication with ALS patients who are "Locked-In," meaning they are in advanced stages of the disease where the brain is conscious and functioning, but they are unable to move any muscles, including the eye Take a closer look.
Columbia University Medical Center: Stem Cells Are Immortal, But They Do Get Old

Though older people do not have less blood than their younger counterparts, something in old blood is indeed lacking, according to Emmanuelle PasseguĂ©, PhD, the new director of theColumbia Stem Cell Initiative (CSCI) and one of the nation's foremost authorities on hematopoietic stem cells (HSCs), blood-forming stem cells that originate in the bone marrow.   Take a closer look.
University at Buffalo Jacobs School of Medicine: Microbiome Study Finds Children with Type 2 Diabetes More Likely to Have Poor Oral Health

The first study of oral health in children with Type 2 diabetes, including those who are obese, has found that these children tend to have poorer oral health than children who do not have Type 2 diabetes Take a closer look.
Albert Einstein College of Medicine: MicroRNAs Show Promise for Revealing Radiation Exposure and Likelihood of Survival

Ionizing radiation incidents-nuclear war, nuclear accidents or terrorist dirty bombs, for example-can cause mass fatalities. Since resources for medical countermeasures are limited, it's critically important to swiftly and accurately triage those victims most likely to benefit from treatment. A new study that published online today in Science Translational Medicine found that microRNAs (miRNAs) in serum may help in that effort.   Take a closer look.
Weill Cornell Medicine Investigators Named to Stand Up 2 Cancer's Colorectal Dream Team

The interdisciplinary team, funded by a grant worth up to $12 million, brings together researchers from six institutions who will focus on three complementary areas of research that have the potential to affect all stages of colorectal cancer, from the pre-malignant lesion to patients diagnosed with metastatic disease.   Take a closer look.
New York Medical College: We Want a Federal Budget Where the Trade-Offs Support Life, not Death

Chancellor Edward C. Halperin on the proposed federal budget at   Take a closer look.
University of Rochester Medical Center: FDA Approves New Eczema Drug

People who suffer from eczema have new hope for relief with the U.S. Food and Drug Administration's approval of a "game changing" medication tested at URMC.  The new drug, Dupilumab, is the first treatment to show significant, lasting results for adults whose lives are disrupted by moderate to severe eczema or atopic dermatitis (AD) .Take a closer look.
New York Medical College Faculty Spotlight: William H. Frishman, M.D.

William H. Frishman, M.D., is the Barbara and William Rosenthal Professor and Chairman of the Department of Medicine and professor of pharmacology at New York Medical College. He also serves as director of medicine at Westchester Medical Center.   Take a closer look.